Emerging ASX gems conference presentation
Arovella CEO and MD, Dr Michael Baker, will provide an overview of Arovella’s iNKT cell therapy platform and how its technology provides important advantages over existing T-cell therapies and has the potential to be applied to both blood cancers and solid tumours.
